Fig. 7

LMY reduces hepatic lipid accumulation through the inhibition of Yap1 activity(A) Typical oil red O staining images showing the alleviation of lipid accumulation in LMY cells treated with or without a Yap1 inhibitor (verteporfin). (B) Quantification of the alleviating effect of LMY on lipid accumulation in the presence or absence of the Yap1 inhibitor. The average oil red O staining intensity of HCF-fed zebrafish treated with DMSO was defined as 100%. (C) Scheme of the transgenic plasmid used to induce activated Yap1 overexpression in the zebrafish liver. (D) Quantification of the transcript level of Yap1 in the livers of WT and Yap1-overexpressing zebrafish livers. (E) Typical oil red O staining images showing lipid accumulation in HCF diet-fed WT and Yap1 liver-overexpressing zebrafish with or without LMY. (F) Quantification of lipid accumulation in HCF diet-fed WT and Yap1-overexpressing zebrafish with or without LMY. The average oil red O staining intensity of HCF-fed WT zebrafish was defined as 100%. The numbers in each image refer to the number of fish in each treatment group. (G) Quantification of SREBF2, HMGCR, FASN, and FOXM1 in WT and Yap1-overexpressing zebrafish treated with or without LMY. (H) HOMA-IR indices of zebrafish cultured in the presence or absence of Yap1 or FOXM1 inhibitors. All these experiments were conducted three times in a double-blind manner, and the quantification results are presented as the mean±SEM. *P<0.05, **P <0.01, ***P<0.001, and ****P<0.0001. ns, no significance.